2021
Medication strategies in first episode psychosis patients: A survey among psychiatrists
Kikkert M, Veling W, de Haan L, Begemann M, de Koning M, Sommer I, de Haan L, Veling W, van Os J, Smit F, Begemann M, Schuite‐Koops S, Marcelis M, Kikkert M, van Beveren N, Boonstra N, Rosema B, Bakker P, Gülöksüz S, Lokkerbol J, Brand B, Gangadin S, Geraets C, Hag E, Oomen P, Voppel A, van Amelsvoort T, Bak M, Been A, van den Bosch M, van den Brink T, Faber G, Grootens K, de Jonge M, Knegtering H, Kurkamp J, Mahabir A, Pijnenborg G, Staring T, Vaes W, Veen N, Veerman S, Wiersma S, Sommer I. Medication strategies in first episode psychosis patients: A survey among psychiatrists. Early Intervention In Psychiatry 2021, 16: 139-146. PMID: 33754470, PMCID: PMC9292219, DOI: 10.1111/eip.13138.Peer-Reviewed Original ResearchConceptsFirst psychotic episodeMedication discontinuationMedication strategiesPsychotic episodeFirst-episode psychosis patientsEpisode psychosis patientsSubstantial practice variationFirst-episode patientsMonths of remissionFirst-episode psychosisSpecific treatment strategiesSubsample of patientsPractice of cliniciansMaintenance therapyEarly discontinuationPsychosis patientsAntipsychotic drugsEpisode psychosisTreatment strategiesReduced dosePractice variationLong-term effectsSame doseDiscontinuationMost guidelines
2020
S115. EVALUATION OF THE CLINICAL UTILITY OF SYMPTOM DIMENSIONS ON LONG-TERM CLINICAL AND FUNCTIONAL OUTCOMES IN FIRST EPISODE PSYCHOSIS
Bor E, Quattrone D, Rodriguez V, Alameda L, Guloksuz S, Murray R. S115. EVALUATION OF THE CLINICAL UTILITY OF SYMPTOM DIMENSIONS ON LONG-TERM CLINICAL AND FUNCTIONAL OUTCOMES IN FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin 2020, 46: s78-s78. PMCID: PMC7234345, DOI: 10.1093/schbul/sbaa031.181.Peer-Reviewed Original ResearchLength of hospitalisationCase-control studyClinical outcomesFunctional outcomeClinical utilityDepressive symptomsSymptom dimensionsPositive symptomsNegative symptomsGlobal functioningFirst-episode psychosis patientsMulticentre case-control studyBaseline positive symptomsLong-Term ClinicalRisk of hospitalisationEpisode psychosis patientsPoor clinical outcomeFirst-episode psychosisCurrent clinical utilityPotential clinical utilitySymptom-based approachFurther outcome researchHospital admissionBetter prognosisProspective study
2019
Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort)
Pandit R, Cianci D, Hark S, Rossum I, Ebdrup B, Broberg B, Garcia‐Portilla M, Bobes J, Vinkers C, Kahn R, Guloksuz S, Huitema A, Luykx J. Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort). Acta Psychiatrica Scandinavica 2019, 140: 283-290. PMID: 31323113, PMCID: PMC6771865, DOI: 10.1111/acps.13074.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis patientsPsychosis patientsWeight gainSchizophreniform disorderAntipsychotic-induced weight gainFirst-episode patientsManagement of schizophreniaLower baseline weightMultivariable regression modelsWeight-reducing strategiesOptimization of treatmentRegression modelsMajor depression disorderPhenotypic factorsAmisulpride treatmentBaseline weightEurope (Syst-Eur) trialMost antipsychoticsDepression disorderYoung subjectsBody weightPatientsBetter efficacyYounger ageAIWG